TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
(main) Inclusion Criteria:~* age 18 - 75 years at screening~* ability to give written consent, informed written consent~* negative pregnancy test at screening~* therapy-refractory Myasthenia Gravis (generalized) or Systemic Lupus Erythematosus or Rheumatoid Arthritis~(main) Exclusion Criteria:~* Belimumab therapy within the last 6 months~* B-cell-depletion therapy within the last 9 months~* heart or kidney insufficiency~* known intolerability to Bortezomib~* participation in another interventional trial within the last 3 months~* liver cirrhosis~* preexistent sensory or motor polyneuropathy ≥ degree 2 (NCI CTC AE criteria), within 14 days before screening~* hints on clinically apparent herpes zoster reactivation~* active systemic infection, or viral infection (CMV, EBV) within last 6 month before screening~* serologically active hepatitis B and /or C, known HIV infection~* tumor disease currently or within last 5 years~* clinically relevant liver, kidney or bone marrow function disorder~* pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bortezomib (Velcade) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Functional Recovery After Distal Intra-articular Radius Fracture With a Dorsal Tilt Treated With an Anterior Plate Versus a Posterior Plate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have provided written informed consent~* Patients older than 45 years~* Patients presenting a closed intra-articular fracture of the distal radius with a dorsal tilt (stages B2, C1, C2 and C3)~Exclusion Criteria:~* Adults under guardianship~* Patients without national health insurance cover~* Pregnant or breast-feeding women~* Patients presenting other injuries in the same upper limb~* Patients presenting injuries of the wrist or hand (scapholunate injury, fracture of the carpal bone or fingers)~* Pre-trauma paralysis of the limb~* Open fracture~* Fracture with palmer tilt or extra-articular

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Osteosynthesis using a posterior plate (Type: ACTIVE_COMPARATOR): None
- Osteosynthesis using an anterior plate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: OSA Screen Negative With Spinal Duramorph

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* OSA screen negative per hospital protocol~* age 18 or greater~* BMI\>35~* consent to participate to wear capnography and pulse oximetry monitoring devices post delivery~Exclusion Criteria:~* Spanish speaking only~* under age 18~* contraindication to receiving drugs utilized in delivery anesthetic

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- capnography monitoring (Type: OTHER): single arm, all subjects receiving duramorph will receive capnography monitoring

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine for Relapse Prevention in Recurrent Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years old~* Hamilton Rating Scale for Depression, 24-item (HRSD-24) score of ≥21~* Voluntary admission for treatment of acute depressive episode~* Meet DSM-IV criteria for recurrent depressive disorder (RDD): ≥2 previous depressive episodes with at least 2-months(consecutive) subthreshold or no symptoms in between PLUS(to enrich the sample for those at high risk for relapse) must also have experienced ≥3 major depressive episodes(including index episode) within the previous 2 years~For the randomised pilot trial, RDD patients must have:~* received antidepressant treatment for the acute depressive episode(pharmacological, psychotherapeutic or multidisciplinary)~* ≥60% decrease from baseline HRSD-24 score and score ≤16~* Standardised Mini-Mental State Examination (sMMSE) score of ≥24~* able to provide informed consent~Exclusion Criteria:~* Current involuntary admission~* Medical condition rendering unfit for ketamine/midazolam~* Active suicidal intention~* Dementia~* History of Axis 1 diagnosis other than RDD~* Electroconvulsive therapy (ECT) for treatment of current depressive episode~* Alcohol/substance abuse in previous six months~* Pregnancy or inability to confirm use of adequate contraception during the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Trial Interventions: participants will receive four two-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
- Midazolam (Type: ACTIVE_COMPARATOR): Trial Interventions: participants will receive four two-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Blood culture samples determined to be Gram-positive from subjects aged 18+, inclusive, with any of the following bottle types:~   * bioMerieux BacT/ALERT® Standard Aerobic and Anaerobic~  * bioMerieux BacT/ALERT® FAN Aerobic and FAN Anaerobic~2. Completion of the KeyPathTM BTA Test on the sample.~3. Completion of the reference method for S. aureus identification (tube coagulase and Remel Staphaurex ) and completion of the reference method for methicillin resistance determination (30 µg cefoxitin disc diffusion) for S. aureus positive samples.~Exclusion Criteria:~1. Samples from blood culture positives over 24 hours from alarm~2. Samples deemed contaminated.~3. Violations and/or deviations from the KeyPathTM BTA Test protocol and/or other included test protocols under study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: None): 1. Comparison of S. aureus to the reference methods for S. aureus (tube coagulase and Staphaurex.)~2. Comparison to the reference method (30 ug cefoxitin disc diffusion).
- KeyPath Test Group (Type: None): All specimens collected that meet the inclusion criteria will be tested using the KeyPath BTA Test.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* IGF-1 ≥1.3 x upper limit normal (ULN)~* Nadir serum GH concentration ≥0.4 ng/mL in an oral glucose tolerance test (OGTT)~* Patient must have documentation supporting the diagnosis of acromegaly, including elevated GH and/or insulin-like growth factor-1 (IGF-1) levels.~Exclusion Criteria:~* The patient has received long acting somatostatin analogues within 6 months of study entry~* The patient has undergone radiotherapy at any time prior to study entry~* The time between pituitary surgery (if any) and study entry is less than 6 weeks~* The patient suffers from macroadenoma with visual field defects due to chiasmatic compression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BIM 23A760 1 mg (Type: EXPERIMENTAL): None
- BIM 23A760 2 mg (Type: EXPERIMENTAL): None
- BIM 23A760 4 mg (Type: EXPERIMENTAL): None
- BIM 23A760 6 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients over age 18~2. Intra or extrahepatic cholangiocarcinoma confirmed by biopsy/brushings, biliary aneuploidy demonstrated by FISH, or elevated CA 19-9 greater than 100 ng/mL in the presence of a radiographic malignant stricture~3. Deemed surgically unresectable by a surgical oncologist~4. Malignant disease encompassable within a single radiation field~5. ECOG 0-2~6. Laboratory values: Hemoglobin ≥ 8.0 (can be transfused to attain this value), Granulocytes \> 1,500, platelets \> 100,000/ul~Exclusion Criteria:~1. Chemotherapy within one month of starting radiation therapy~2. Previous abdominal radiotherapy~3. Uncontrolled infection or severe active comorbid disease~4. Previous malignancy in the past five years, excluding nonmelanoma skin cancers and in situ cervical, bladder or uterine cancer~5. Distant metastatic disease (outside regional lymph nodes)~6. Pregnancy or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): All participants enrolled.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma (MM)~* Eligible for autologous transplantation~* Patients in first or second partial remission (PR) or complete remission (CR)~* Patients who have received ≦2000 rads of prior radiation therapy~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Recovered from all acute toxic effects of prior chemotherapy~* White blood cells (WBC) \>3.0\*10\^9/l~* Absolute polymorphonuclear leucocyte (PMN) count \>1.5\*10\^9/l~* Platelet (PLT) count \> 150\*10\^9/l~* Serum creatinine ≦2.2 mg/dl~* Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and total bilirubin \<2 x upper limit of normal (ULN)~* Negative for HIV~* Signed informed consent~* Patients of childbearing potential agree to use an approved form of contraception~Exclusion Criteria:~* Patient received 2 or more alkylating agents, such as VBMCP (a combination of Vincristine, BCNU (Bis-Chloronitrosourea), Melphalan, Cyclophosphamide, and Prednisone)~* Patient received a total dose of ≧200 mg of prior melphalan~* A co-morbid condition which, in the view of the investigators, renders the patient at high risk from treatment complications~* Patient has failed previous collections or collection attempts~* A residual acute medical condition resulting from prior chemotherapy~* Brain metastases or carcinomatous meningitis~* Acute infection~* Fever (temperature \>38 °C / 100.4 °F)~* Hypercalcemia (\>1mg/dl above ULN)~* Positive pregnancy test in female patients~* Lactating females~* Patients of childbearing potential unwilling to implement adequate birth control~* Patients whose actual body weight exceeds 175% of their ideal body weight~* History of ventricular arrhythmias~* Patient received thalidomide within 10 days prior to receiving the first dose of plerixafor~* Patients who previously received experimental therapy within 4 weeks of enrolling in this protocol or who are currently enrolled in another experimental protocol during the mobilization phase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Participants with Multiple Myeloma (MM) (Type: EXPERIMENTAL): Participants with MM who were eligible for autologous peripheral blood stem cell transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: SOX as Salvage Treatment in Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age range: 18-75 years old~* Histological confirmed incurable relapsed or metastatic nasopharyngeal carcinoma~* Prior exposure of at least one line of platinum-containing regimen~* ECOG performance status 0-1~* Life expectancy of more than 3 months~* Bone marrow function: ANC≧1.5×109/L, PLT≧100×109/L, Hb≧80g/L~* Liver function: total bilirubin, ALT and AST \<1.5×UNL~* Renal function: Cr\<1.5×UNL, CCR≧50ml/min~* Without \> 1 grade of neuropathy~Exclusion Criteria:~* With curable treatment option~* With CNS involvement~* Prior platinum exposure only in neo-adjuvant/adjuvant setting or concurrently used with radiotherapy~* Treated with \> 2 lines of palliative chemotherapy~* With prior exposure of S-1 or oxaliplatin~* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix~* Significant active infection~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- S-1 plus oxaliplatin (Type: EXPERIMENTAL): S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks for 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically documented pancreatic adenocarcinoma deemed unresectable due to local involvement of vessels or organs~* Patients with a clear clinical diagnosis of localized pancreatic cancer deemed unresectable, who have undergone at least 2 biopsies which were not diagnostic of adenocarcinoma, may be entered at the discretion of the principal investigator.~* No prior chemotherapy or abdominal radiation therapy.~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1~* Clinically measurable or evaluable disease.~* Life expectancy of at least 12 weeks.~* Adequate bone marrow reserve, granulocyte count \>= 1500/uL, platelet count \>= 100,000/uL, hemoglobin \>= 9 g/dL.~* Adequate renal function with creatinine =\< 1.5 times upper limit of normal (ULN)~* Adequate biliary function with bilirubin \< 3.0 g/dL (including patients who have been bypassed or treated with percutaneous drainage), serum glutamic pyruvic transaminase (SGPT) (alanine transaminase) =\< 2.5~* Age \> 18 years~* Signed informed consent.~* No known allergy to one of the study drugs~* For female patient of childbearing potential, neither pregnant nor breastfeeding, and under active contraception~* No prior malignancy within last 5 years~* No central nervous system metastases~* No peripheral neuropathy \> grade2~* No other serious concomitant illness~Exclusion Criteria:~* Active infection or uncontrolled infection~* Presence of metastatic disease.~* Inadequate organ function as discussed above.~* Pregnancy~* Serious concomitant systemic disorder.~* Use of any investigational agent within a month of treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxaliplatin+ 5FU+ radiation (RT) /surgery /FOLFOX 6 (Type: EXPERIMENTAL): Concurrent chemoradiation before surgery and FOLFOX6 regimen after surgery~Radiation (RT) 180cGy daily x 5 days/week x 5 weeks, then additional 540 cGy in 3 fractions over a half week to pancreatic portal;~Combined with :~5FU 200 mg/m\^2 daily by continuous intravenous infusion (CIV) x 5 weeks and weekly Oxaliplatin 60 mg/m\^2, IV for 5 weeks (in Phase I, 30, 40, 50, and 60 mg/m\^2 Oxaliplatin were tested).~Observation for 2 weeks to assess dose-limiting toxicity (DLT)/Response. Surgery if deemed resectable.~Then modified FOLFOX 6 for 6 cycles (2 weeks/cycle):~Day 1 hour 0: Oxaliplatin 85 mg/m\^2 intravenously (IV) + Leucovorin 350 mg IV over 2 hours; hour 2: 5FU 400 mg/m\^2 IV bolus followed by 2400 mg/m\^2 IV over 46 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Infusion Diabetes Ulcer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients are eligible for inclusion if the following criteria are fulfilled:~  * Patients with diabetes type 1 or type 2.~ * Older than 18 years.~ * Patients scheduled for cardio- vascular surgery and/ or acute ulcer infection.~ * Hyperglycaemia: Capillary P-glucose above 8 mmol/L.~ * Informed consent obtained.~Exclusion Criteria:~* Patients having any of the following at randomization will not be included in the study:~  * Unconsciousness: not possible to wake up.~ * Ketoacidosis: pH less or equal to 7.30.~ * Hyperosmolar syndrome: S-Na more or equal to 150 mmol/L.~ * Kidney failure: calculated GFR \< 30 mL/min.~ * Pregnancy.~ * Mental condition making the subject unable to understand the concepts and risk of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Insulin infusion (aspart) (Type: EXPERIMENTAL): None
- Standard care (Type: NO_INTERVENTION): Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fecal Microbiota Transplantation for Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Mild to moderate UC.~Exclusion Criteria:~* Antibiotic exposure in the last 3 months.~* Biologic or immunomodulatory therapy within the last 3 months.~* Corticosteroid therapy or probiotics within the last 2 weeks.~* Severely active disease (defined as Mayo scores of 10 or greater, or patients with endoscopic disease activity scores of 3 or greater).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fecal Microbiota Transplantation (Type: EXPERIMENTAL): Fecal Microbiota Transplantation by colonoscopic delivery of stool to the right colon.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: UVB Phototherapy Treatment of Oral Chronic GVHD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with oral chronic graft-versus-host disease~* 4 years of age or older~* Stable cGVHD medication regimen for the four weeks prior to study enrollment~Exclusion Criteria:~* New immunomodulatory medications or increasing dosage of current immunomodulatory medications during the four weeks prior to study enrollment~* Concurrent extracorporeal photopheresis.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues